现有CAP认证要求对分子肿瘤学中机器学习方法临床实施的普遍适用性
该研究回顾CAP分子病理学与通用实验室实践检查表,识别可适用于机器学习(ML)分子肿瘤学检测临床采用的认证要求,并总结验证、复验、质量管理、基础设施和分析程序相关条款;文献综述显示ML应用包括DNA甲基化谱分析、变异调用、微卫星不稳定检测、突变特征分析和组织病理图像变异预测,结论为现有CAP要求可作为ML检测临床实施的一般指南。
要点
- 现有CAP认证框架中用于传统分子肿瘤学检测验证与维护的组件同样适用于ML检测。
- ML在分子肿瘤学中的当前应用包括DNA甲基化谱分析、变异调用和微卫星不稳定检测等。
- 尽管ML有特殊考虑,现有CAP要求可作为ML检测临床实施的一般指南。
核心结论
- 尽管ML方法有特定考虑,现有CAP要求可作为分子肿瘤学中ML检测临床实施的一般指南。
研究设计与样本
- 综述CAP分子病理学、All Common和Laboratory General检查表中与分子病理学和通用实验室实践相关的认证要求,并结合文献综述评估ML在分子肿瘤学检测中的应用实例。
主要发现
- CAP认证框架中用于传统分子肿瘤学检测验证和维护的组件与ML检测的临床实验室实施相关。
- ML在分子肿瘤学检测中的当前和新兴应用包括DNA甲基化谱分析用于中枢神经系统肿瘤分类、变异调用、微卫星不稳定检测、突变特征分析和基于组织病理图像的变异预测。
关键数值与推荐
- CAP检查表中适用于ML分子肿瘤学检测验证、复验、质量管理、基础设施和分析程序的通用要求已被总结。
临床怎么用
- 临床实验室可采用现有CAP认证要求作为ML分子肿瘤学检测实施的一般指南。
局限性
- 专门针对临床实验室使用ML的认证要求仍处于早期发展阶段。
- 目前ML在分子肿瘤学中的大部分活动处于早期临床实施阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The College of American Pathologists (CAP) accreditation requirements for clinical laboratory testing help ensure laboratories implement and maintain systems and processes that are associated with quality. Machine learning (ML)-based models share some features of conventional laboratory testing methods. Accreditation requirements that specifically address clinical laboratories' use of ML remain in the early stages of development. OBJECTIVE.—: To identify relevant CAP accreditation requirements that may be applied to the clinical adoption of ML-based molecular oncology assays, and to provide examples of current and emerging ML applications in molecular oncology testing. DESIGN.—: CAP accreditation checklists related to molecular pathology and general laboratory practices (Molecular Pathology, All Common and Laboratory General) were reviewed. Examples of checklist requirements that are generally applicable to validation, revalidation, quality management, infrastructure, and analytical procedures of ML-based molecular oncology assays were summarized. Instances of ML use in molecular oncology testing were assessed from literature review. RESULTS.—: Components of the general CAP accreditation framework that exist for traditional molecular oncology assay validation and maintenance are also relevant for implementing ML-based tests in a clinical laboratory. Current and emerging applications of ML in molecular oncology testing include DNA methylation profiling for central nervous system tumor classification, variant calling, microsatellite instability testing, mutational signature analysis, and variant prediction from histopathology images. CONCLUSIONS.—: Currently, much of the ML activity in molecular oncology is within early clinical implementation. Despite specific considerations that apply to the adoption of ML-based methods, existing CAP requirements can serve as general guidelines for the clinical implementation of ML-based assays in molecular oncology testing.
引用
- Furtado LV, Ikemura K, Benkli CY, et al. General Applicability of Existing College of American Pathologists Accreditation Requirements to Clinical Implementation of Machine Learning-Based Methods in Molecular Oncology Testing. Arch Pathol Lab Med. 2025. PMID: 38871357. doi:10.5858/arpa.2024-0037-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。